Table 3.
Cox univariate and multivariate analyses demonstrating the influence of clinicopathological parameters and TP gene expression on time to progression
| |
Univariate |
Multivariate |
|||
|---|---|---|---|---|---|
| HR | 95% CI P* | HR | 95% CI | P* | |
|
Gender |
|
|
|
|
|
| Male |
1 |
|
1 |
|
|
| Female |
1.46 |
0.95-2.25 NS |
1.48 |
0.94-2.34 |
NS |
|
Age (years) |
1.00 |
0.99-1.03 NS |
1.01 |
0.98-1.04 |
NS |
|
Tumour location |
|
|
|
|
|
| Rectum |
1 |
|
1 |
|
|
| Colon |
1.49 |
0.96-2.34 NS |
1.21 |
0.74-2.01 |
NS |
|
Tumour differentiation |
|
|
|
|
|
| Well/Medium |
1 |
|
1 |
|
|
| Poor |
1.65 |
1.03-2.61 |
1.50 |
0.92-2.42 |
|
| Mucinous |
2.04 |
0.84-4.23 NS |
2.12 |
0.83-4.78 |
NS |
|
TP gene expression |
|
|
|
|
|
| High |
1 |
|
1 |
|
|
| Low |
1.78 |
1.15-2.79 < 0.05 |
1.61 |
1.01-2.61 |
<0.05 |
|
ECOG performance status |
|
|
|
|
|
| 0 |
1 |
|
1 |
|
|
| 1 |
1.09 |
0.62-1.81 |
1.18 |
0.67-1.98 |
|
| 2-3 |
6.51 |
2.44-14.5 < 0.05 |
7.17 |
2.60-16.8 |
<0.05 |
|
Chemotherapy |
|
|
|
|
|
| Combination treatment† |
1 |
|
1 |
|
|
| Single treatment‡ | 1.29 | 0.78-2.07 NS | 1.11 | 0.59-2.05 | NS |
Abbreviation: HR Hazard Ratio, CI Confidence interval, TP Thymidine Phosphorylase, ECOG Eastern Cooperative Oncology Group *Statistical method; Cox proportional hazards regression. †5-fluorouracil or capecitabine in combination with oxaliplatin or irinotecan; ‡5-fluorouracil or capecitabine.